$150M Public Offering: uniQure Seeks Cash Amid Gene Therapy Push
Event summary
- $150M underwritten public offering of ordinary shares and pre-funded warrants announced June 22, 2026.
- 30-day option for underwriters to purchase additional $22.5M in shares.
- Offering pursuant to automatically effective shelf registration statement on Form S-3 filed January 7, 2025.
- Proceeds to support pipeline of gene therapies including Huntington's disease and Fabry disease treatments.
The big picture
uniQure's $150M offering comes as gene therapy companies increasingly turn to public markets for growth capital amid high development costs. The move follows its approval for hemophilia B treatment, positioning it in a competitive field where execution on pipeline programs will determine long-term viability.
What we're watching
- Pipeline Execution
- Whether uniQure can advance its Huntington's disease and Fabry disease programs with the new capital.
- Market Conditions
- How broader financial market volatility may impact the completion of this offering on anticipated terms.
- Competitive Positioning
- The pace at which uniQure can differentiate itself in the crowded gene therapy space with its current portfolio.
Related topics